| Announced on | Meeting on |
| Aug 06, 2024 | Aug 13, 2024 |
| Quarterly Results | |
| Jul 24, 2024 | Jul 31, 2024 |
| Others | |
| May 22, 2024 | May 30, 2024 |
| Audited Results | |
| Feb 06, 2024 | Feb 13, 2024 |
| Quarterly Results | |
| Nov 06, 2023 | Nov 14, 2023 |
| Quarterly Results | |
Ortin Labs - Ortin Laboratories Share Price
NSE
- Open21.94
- High21.94
- Low21.26
- Prev Close21.62
- Volume62,877
- VWAP(₹)21.55
Ortin Labs share price insights
Losing Shareholder's Money
Company has reported a negative ROE for 3 consecutive years. (Source: Standalone Financials)PAT: Troublesome Times
Company has posted a loss of Rs 0.1 cr for the 4th consecutive quarter. (Source: Standalone Financials)Stock Returns vs Nifty Smallcap 100
Stock gave a 3 year return of -24.3% as compared to Nifty Smallcap 100 which gave a return of 91.39%. (as of last trading session)Employee & Interest Expense
Company has spent 22.83% of its operating revenues towards interest expenses and 26.62% towards employee cost in the year ending Mar 31, 2024. (Source: Standalone Financials)Ortin Labs Share Price Update
Ortin Laboratories Ltd. share price moved down by -0.75% from its previous close of Rs 21.62. Ortin Laboratories Ltd. stock last traded price is 21.46
Share Price Value Today/Current/Last 21.46 Previous Day 21.62
Ortin Labs Share Price Returns
| 1 Day | -0.75% |
| 1 Month | -6.29% |
| 3 Months | 27.36% |
| 1 Year | 9.49% |
| 3 Years | -24.3% |
| 5 Years | 142.49% |
Key Metrics
| PE Ratio(x) | -2.14 |
| EPS - TTM(₹) | -10.04 |
| MCap(₹ Cr.) | 17.45 |
| MCap Rank | 102 |
| PB Ratio(x) | 6.23 |
| Div Yield(%) | 0.00 |
| Face Value(₹) | 10.00 |
| 52W High(₹) | 26.35 |
| 52W Low(₹) | 16.20 |
| MCap/Sales | 6.86 |
| Beta(1 Month) | -0.21 |
| BV/Share(₹) | 3.47 |
Ortin Labs Share Recommendations
No Recommendations details available for this stock.
Check out other stock recos.
ADVERTISEMENT
Ortin Labs News & Analysis
ADVERTISEMENT
Ortin Labs Financials
Consolidated
Jun 2012 Mar 2012 Total Income 15.96 19.77 Total Income Growth (%) -19.23 -0.26 Total Expenses 14.18 16.46 Total Expenses Growth (%) -13.83 -5.77 EBIT 1.78 3.31 EBIT Growth (%) -46.11 40.59 Profit after Tax (PAT) 0.44 1.43 PAT Growth (%) -69.09 18.57 EBIT Margin (%) 11.17 16.74 Net Profit Margin (%) 2.76 7.21 Basic EPS (₹) 0.26 0.84 All figures in Rs Cr, unless mentioned otherwise
InsightsPAT: Troublesome Times
Company has posted a loss of Rs 0.1 cr for the 4th consecutive quarter. (Source: Standalone Financials)Employee & Interest Expense
Company has spent 22.83% of its operating revenues towards interest expenses and 26.62% towards employee cost in the year ending Mar 31, 2024. (Source: Standalone Financials)
Annual FY 2012 Total Assets 81.52 Total Assets Growth (%) - Total Liabilities 57.01 Total Liabilities Growth (%) - Total Equity 24.51 Total Equity Growth (%) - Current Ratio (x) 1.11 Total Debt to Equity (x) 0.58 Contingent Liabilities 0.00 All figures in Rs Cr, unless mentioned otherwise
Annual FY 2012 Net Cash flow from Operating Activities 0.00 Net Cash used in Investing Activities 0.00 Net Cash flow from Financing Activities 0.00 Net Cash Flow 0.00 Closing Cash & Cash Equivalent 0.00 Closing Cash & Cash Equivalent Growth (%) - Total Debt/ CFO (x) - All figures in Rs Cr, unless mentioned otherwise
Annual FY 2012 Return on Equity (%) 18.85 Return on Capital Employed (%) 34.77 Return on Assets (%) 5.67 Interest Coverage Ratio (x) 3.63 Asset Turnover Ratio (x) - Price to Earnings (x) 10.44 Price to Book (x) 1.97 EV/EBITDA (x) 5.27 EBITDA Margin (%) 13.81 InsightsLosing Shareholder's Money
Company has reported a negative ROE for 3 consecutive years. (Source: Standalone Financials)
ADVERTISEMENT
Peer Comparison
NAME 1D 1W 1M 3M 1Y 3Y 5Y Ortin Labs Stock Performance -0.75 7.30 -1.65 25.50 9.77 -24.30 141.12 Brooks Labs Stock Performance -4.15 -0.53 30.18 40.67 27.44 -3.83 244.10 Bal Pharma Stock Performance -1.13 27.22 28.61 50.33 56.90 61.69 286.82 Alpa Labs Stock Performance 0.04 3.84 15.65 21.14 35.50 110.64 653.03 Vaishali Pharma Stock Performance 2.53 21.10 21.21 33.82 54.84 400.36 577.01 All values in %
Insights
Stock Returns vs Nifty Smallcap 100
Stock gave a 3 year return of -24.3% as compared to Nifty Smallcap 100 which gave a return of 91.39%. (as of last trading session)Stock Returns vs Nifty Pharma
Stock generated -24.3% return as compared to Nifty Pharma which gave investors 64.02% return over 3 year time period. (as of last trading session)
Mutual Funds Ownership
No Data Available
ADVERTISEMENT
Corporate Actions
Board Meeting
Quarterly Results
Aug 06, 2024
Board Meeting
Others
Jul 24, 2024
Board Meeting
Audited Results
May 22, 2024
Announced on Ex-Date Dividend% Jun 05, 2013 Sep 24, 2013 2% Aug 31, 2012 Sep 24, 2012 5% Sep 29, 2011 Oct 13, 2011 5% Aug 26, 2010 Sep 23, 2010 8% Sep 02, 2009 Sep 23, 2009 8% No Data Available
No Data Available
No Data Available
Announced on Meeting on Mar 14, 2024 Apr 11, 2024 - Nov 22, 2023 Dec 14, 2023 - Sep 12, 2023 Sep 30, 2023 A.G.M. Jan 24, 2020 Feb 26, 2020 - Aug 14, 2019 Sep 30, 2019 Book closure from Sep 21, 2019 to Sep 30, 2019
ADVERTISEMENT
About
Ortin Laboratories Ltd., incorporated in the year 1986, is a Small Cap company (having a market cap of Rs 17.45 Crore) operating in Pharmaceuticals sector.
Ortin Laboratories Ltd. key Products/Revenue Segments include Drugs & Pharmaceuticals for the year ending 31-Mar-2023.
For the quarter ended 30-06-2024, the company has reported a Standalone Total Income of Rs .21 Crore, down 31.65 % from last quarter Total Income of Rs .31 Crore and down 86.58 % from last year same quarter Total Income of Rs 1.57 Crore. Company has reported net profit after tax of Rs -.10 Crore in latest quarter.
The company’s top management includes Mr.Murali Krishna Rayaprolu, Mr.S Murali Krishna Murthy, Mr.S Srinivas Kumar, Mr.S Balaji Venkateswarlu, Mr.B Gopal Reddy, Ms.Pottur Sujatha, Mr.S Srinivas Kumar. Company has Sathuluri & Co. as its auditors. As on 30-06-2024, the company has a total of .81 Crore shares outstanding.
About Ortin Labs
Ortin Laboratories Ltd., incorporated in the year 1986, is a Small Cap company (having a market cap of Rs 17.45 Crore) operating in Pharmaceuticals sector. Ortin Laboratories Ltd. key Products/Revenue Segments include Drugs & Pharmaceuticals for the year ending 31-Mar-2023.For the quarter ended 30-06-2024, the company has reported a Standalone Total Income of Rs .21 Crore, down 31.65 % from last quarter Total Income of Rs .31 Crore and down 86.58 % from last year same quarter Total Income of Rs 1.57 Crore. Company has reported net profit after tax of Rs -.10 Crore in latest quarter.The company’s top management includes Mr.Murali Krishna Rayaprolu, Mr.S Murali Krishna Murthy, Mr.S Srinivas Kumar, Mr.S Balaji Venkateswarlu, Mr.B Gopal Reddy, Ms.Pottur Sujatha, Mr.S Srinivas Kumar. Company has Sathuluri & Co. as its auditors. As on 30-06-2024, the company has a total of .81 Crore shares outstanding.
Industry
Key Indices Listed On
-
Address
D. No. 1-8-B4, Ground Floor,F3 HIG, Block-4, Street No.3,Baghlingampally,Hyderabad, Telangana - 500044
Executive Leadership
MK
Murali Krishna Rayaprolu
Chairman & Ind.DirectorSM
S Murali Krishna Murthy
Managing DirectorSS
S Srinivas Kumar
Whole Time DirectorSB
S Balaji Venkateswarlu
Non Executive DirectorShow More
Auditors
Mathesh & Ramana
Sathuluri & Co.
Trending in Markets
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.